The global peptide and anticoagulant drugs market is projected to register a CAGR of 3.3% during the forecast period (2022-2028). Key companies operating in the industry are highly inclined toward the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in September 2021, Nimble Therapeutics entered into a strategic research collaboration with Incyte to include the discovery of additional novel peptide therapies. The collaboration leveraged Nimble's proprietary peptide synthesis, screening, and optimization platform coupled with its high chemical diversity and integrated suites of assays to enable faster discovery of compounds for intercellular and extracellular targets ensuring maximal patient impact across multiple disease indications.
Furthermore, in May 2021, ISSAR Pharmaceuticals has decided to license out their peptide-based new chemical entities (NCEs) with pre-IND filing and US patent for various unmet healthcare needs of the population and making it affordable and accessible for better health outcomes. in February 2021, The Stony Brook Study discovered that using an anticoagulation therapy based on blood serum D-dimer levels reduced mortality in critically ill Covid-19 Patients. In September 2020, Mylan N.V has acquired Aspen Pharmacare Holdings Ltd thrombosis business in Europe. The main aim of the acquisition is to expand access to complex injectables by adding sales and marketing to strengthen the company’s reach in hospitals. Moreover, in February 2019, Blackstone Lifesciences launched Anthos Therapeutics, a biopharmaceutical company. This launch aimed to enable next-generation therapies for high-risk cardiovascular patients. Thus, key acquisitions, developments, collaborations, launches, and growth strategies are boosting the growth of the global peptide and anticoagulant drug market.
Browse the full report description “Global Peptide and Anticoagulant Drug Market Size, Share & Trends Analysis Report by Product (Hormonal, Antibiotic, Antifungal, ACE inhibitor, and others) and by Application (Diabetes, Cancer, Osteoporosis, Cardiology, Gynecology, Infectious Diseases, and Others) Forecast (2022-2028)”at https://www.omrglobal.com/industry-reports/peptide-and-anticoagulant-market
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- are Abbott Laboratories, Johnson & Johnson Services Inc, Bayer AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. and others .
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Peptide and Anticoagulant Drug Market Report Segment
By Product
By Application
Global Peptide and Anticoagulant Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World